Walden Biosciences Is A Biotechnology Company Located In Cambridgemassachusettsfocused On Developing Targeted Therapies For Kidney Diseasefounded In 2020The Company Aims To Transform Kidney Disease Treatment By Reversing Its Progression And Helping Patients Return To Their Normal Lives The Company Specializes In Creating Medicines That Target The Kidney Through Novel Biological Pathwaystheir Clinical Stage Program Includes Wal0921A Humanized Monoclonal Antibody That Inhibits Suparwhich Is Involved In Kidney Dysfunctionthis Product Is Currently Being Evaluated In A Phase 2 Study For Chronic Kidney Diseaseincluding Diabetic Nephropathy And Rare Kidney Diseaseswalden Biosciences Has Fully Enrolled The Second Cohort Of This Study And Plans To Initiate A Rare Kidney Diseases Cohort In Early 2025 Walden Biosciences Has Raised $51 Million In Funding And Fosters A Collaborative Culture Driven By Data And Innovationthe Company Actively Participates In Healthcare Conferences To Share Updates On Its Progress And Future Plans
